Editorial: Imaging and the treatment of Crohn's perianal fistulas: to see is to believe.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19956118.
- Also identified by DOI 10.1038/ajg.2009.518.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fistulizing Crohn's disease is associated with significant morbidity. Although treatment has improved over the last decade, there is still considerable room for improvement. One possible method to improve outcomes is to use advanced imaging techniques, such as endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI), to help guide treatment. In this issue, Ng et al. show again the disconnect between cessation of drainage and the actual deep healing that can be appreciated using these imaging techniques. The authors used MRI to help guide the decision on when to alter medical therapy and were able to identify a subset of patients who could discontinue infliximab. Other authors over the last 5-10 years have also shown the benefit of EUS and MRI in these patients. The time has come for us to not only embrace these imaging modalities as valid end points for clinical trials but more importantly as a means to improve outcomes for our patients with fistulizing Crohn's disease.
Medical subject headings
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- Crohn Disease
- Immunosuppressive Agents
- Intestinal Fistula
- Magnetic Resonance Imaging
- Perineum
- Thalidomide